ECOR Logo

electroCore, Inc. (ECOR) 

NASDAQ
Market Cap
$72.56M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
174 of 775
Rank in Industry
24 of 99

Largest Insider Buys in Sector

ECOR Stock Price History Chart

ECOR Stock Performance

About electroCore, Inc.

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in …

Insider Activity of electroCore, Inc.

Over the last 12 months, insiders at electroCore, Inc. have bought $284,612 and sold $0 worth of electroCore, Inc. stock.

On average, over the past 5 years, insiders at electroCore, Inc. have bought $586,931 and sold $5,960 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Goldberger Daniel S (Chief Executive Officer) — $990,349. Errico Thomas J. (director) — $30,595. GANDOLFO JOHN P (director) — $12,860.

The last purchase of 5,000 shares for transaction amount of $30,595 was made by Errico Thomas J. (director) on 2024‑08‑15.

List of Insider Buy and Sell Transactions, electroCore, Inc.

2024-08-15Purchasedirector
5,000
0.0788%
$6.12$30,5950.00%
2024-06-13Purchasedirector
1,000
0.0156%
$6.43$6,430-2.21%
2024-06-05PurchaseChief Executive Officer
38,505
0.6218%
$6.43$247,587-5.43%
2024-01-12PurchaseChief Financial Officer
16,000
$0$0+5.44%
2023-09-15PurchaseChief Executive Officer
1,500
0.0246%
$5.55$8,333+7.96%
2023-08-04PurchaseChief Executive Officer
50,000
$0$0+32.64%
2023-08-02PurchaseChief Executive Officer
50,991
1.0559%
$4.35$221,811+37.10%
2023-03-17PurchaseChief Executive Officer
500
0.011%
$3.43$1,715+72.64%
2023-03-16PurchaseChief Executive Officer
500
0.0106%
$3.46$1,730+65.12%
2023-03-15PurchaseChief Executive Officer
500
0.0108%
$3.55$1,775+63.22%
2023-03-14PurchaseChief Executive Officer
500
0.011%
$3.73$1,865+58.99%
2023-03-13PurchaseChief Executive Officer
500
0.0113%
$3.86$1,930+56.51%
2022-12-14PurchaseChief Executive Officer
5,000
0.0071%
$0.35$1,749+2.65%
2022-12-13Purchasedirector
100,000
0.1382%
$0.33$33,330+4.36%
2022-12-13PurchaseChief Executive Officer
5,000
0.0068%
$0.33$1,649+4.36%
2022-12-12PurchaseChief Executive Officer
5,000
0.0068%
$0.32$1,590+7.70%
2022-12-09PurchaseChief Executive Officer
5,000
0.0067%
$0.30$1,499+12.38%
2022-12-08PurchaseChief Executive Officer
10,000
0.0143%
$0.28$2,777+29.55%
2022-11-29Purchasedirector
25,000
0.0353%
$0.33$8,253+6.31%
2022-11-25Purchasedirector
50,000
0.0678%
$0.31$15,735+7.03%

Insider Historical Profitability

3.6%
Goldberger Daniel SChief Executive Officer
249565
3.8075%
$11.07180+21.16%
Errico Thomas J.director
233818
3.5672%
$11.07100+0.36%
GANDOLFO JOHN Pdirector
50704
0.7736%
$11.0730<0.0001%
POSNER BRIAN MChief Financial Officer
22437
0.3423%
$11.0741<0.0001%
Merck Global Health Innovation Fund, LLC10 percent owner
3346032
51.0487%
$11.0710

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Awm Investment Company Inc$3.4M9.16550,3640%+$00.52
The Vanguard Group$997,720.002.69161,705+4.78%+$45,528.44<0.0001
Renaissance Technologies$410,000.001.1166,516+37.38%+$111,567.14<0.01
International Assets Investment Management Llc$324,482.000.8853,020+49.77%+$107,834.27<0.01
Geode Capital Management$324,687.000.8852,609+1.46%+$4,678.15<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.